News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
839,521 Results
Type
Article (86027)
Company Profile (651)
Press Release (752843)
Section
Business (232460)
Career Advice (4123)
Deals (39702)
Drug Delivery (127)
Drug Development (90834)
Employer Resources (195)
FDA (18025)
Job Trends (17302)
News (395962)
Policy (39663)
Tag
Academia (2981)
Alliances (56708)
Alzheimer's disease (1426)
Approvals (17990)
Artificial intelligence (246)
Bankruptcy (399)
Best Places to Work (12616)
Biotechnology (448)
Breast cancer (241)
Cancer (1870)
Cardiovascular disease (152)
Career advice (3524)
CAR-T (144)
Cell therapy (412)
Clinical research (72671)
Collaboration (742)
Compensation (386)
COVID-19 (2838)
C-suite (185)
Data (1726)
Diabetes (228)
Diagnostics (6831)
Earnings (95561)
Employer resources (166)
Events (128477)
Executive appointments (607)
FDA (19003)
Funding (654)
Gene therapy (294)
GLP-1 (770)
Government (5086)
Healthcare (20830)
Infectious disease (2960)
Inflammatory bowel disease (139)
Interviews (811)
IPO (17769)
Job creations (5183)
Job search strategy (2860)
Layoffs (520)
Legal (10080)
Lung cancer (273)
Manufacturing (271)
Medical device (14502)
Medtech (14507)
Mergers & acquisitions (22296)
Metabolic disorders (633)
Neuroscience (1890)
NextGen: Class of 2025 (7662)
Non-profit (5075)
Northern California (2223)
Obesity (348)
Opinion (263)
Patents (183)
People (64816)
Phase I (22422)
Phase II (31567)
Phase III (23765)
Pipeline (808)
Postmarket research (3551)
Preclinical (10053)
Radiopharmaceuticals (262)
Rare diseases (364)
Real estate (7381)
Regulatory (26422)
Research institute (2647)
Resumes & cover letters (649)
Southern California (1914)
Startups (4284)
United States (20276)
Vaccines (723)
Weight loss (261)
Date
Today (119)
Last 7 days (834)
Last 30 days (2849)
Last 365 days (36490)
2025 (5644)
2024 (37555)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1268)
Arizona (245)
Asia (49792)
Australia (8778)
California (5182)
Canada (1774)
China (437)
Colorado (237)
Connecticut (246)
Europe (114019)
Florida (748)
Georgia (179)
Illinois (532)
Indiana (285)
Maryland (819)
Massachusetts (4038)
Michigan (213)
Minnesota (367)
New Jersey (1467)
New York (1467)
North Carolina (999)
Northern California (2223)
Ohio (180)
Pennsylvania (1159)
South America (1649)
Southern California (1914)
Texas (760)
Utah (157)
Washington State (514)
839,521 Results for "treos bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.
May 8, 2024
·
2 min read
Genetown
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
Treos Bio Limited announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 American Society of Clinical Oncology Annual Meeting.
June 3, 2024
·
7 min read
Press Releases
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
September 10, 2024
·
3 min read
Press Releases
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
February 5, 2025
·
3 min read
Press Releases
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
February 4, 2025
·
3 min read
Press Releases
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
·
5 min read
Press Releases
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
January 28, 2025
·
7 min read
Layoffs
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway
Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.
January 13, 2025
·
1 min read
·
Angela Gabriel
Press Releases
EditCo Bio, Inc. Launches XDel Knockout Cells: Redefining CRISPR Gene Editing Efficiency and Reproducibility
January 28, 2025
·
3 min read
Press Releases
Cadenza Bio, Inc. Announces Members of the Women’s Health Scientific Advisory Board
January 9, 2025
·
2 min read
1 of 83,953
Next
